Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed B.V. stock (symbol: MYNZ) underwent a total of 1 stock splits.
The most recent stock split occured on Dec 03, 2024.
Date | Splite | Multiple |
---|---|---|
2024-12-03 | 1:40 | 1 |